GSK leads the top five companies with access planning to provide medicines to low- and middle-income countries

Percentage of late-stage R&D

projects with access plans

80

79

GSK

Johnson & Johnson

69

63

Pfizer

Takeda

57

Novartis

Percentage of late-stage R&D projects with access plans

80

79

69

GSK

Johnson & Johnson

Pfizer

63

57

Takeda

Novartis

GSK leads the top five companies with access planning to provide

medicines to low- and middle-income countries

Percentage of late-stage R&D projects with access plans

80

79

69

63

57

GSK

Johnson & Johnson

Pfizer

Takeda

Novartis